Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $36.70 to $37.58
• 50-Day Range: $34.93 to $55.37
• 52-Week Range: $34.07 to $62.53
• Volume: 256,160 shs
• Average Volume: 949,859 shs
• Market Capitalization: $3.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $72.64
• Consensus Rating: Moderate Buy

Crinetics Pharmaceuticals Stock Analysis - MarketRank™

Crinetics Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 179th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Crinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Crinetics Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.73) to ($4.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Crinetics Pharmaceuticals is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Crinetics Pharmaceuticals is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Crinetics Pharmaceuticals has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.96% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Crinetics Pharmaceuticals has recently increased by 2.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Crinetics Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Crinetics Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -0.62

Percentage of Shares Shorted

7.96% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Crinetics Pharmaceuticals has recently increased by 2.93%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Crinetics Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

8 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $223,667.00 in company stock.

Percentage Held by Insiders

Only 6.00% of the stock of Crinetics Pharmaceuticals is held by insiders.

Percentage Held by Institutions

98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRNX Stock Analysis - Frequently Asked Questions

How have CRNX shares performed this year?

Crinetics Pharmaceuticals' stock was trading at $51.13 on January 1st, 2025. Since then, CRNX shares have decreased by 27.4% and is now trading at $37.1430.
View the best growth stocks for 2025 here.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.91) by $0.05.

When did Crinetics Pharmaceuticals IPO?

Crinetics Pharmaceuticals (CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' top institutional investors include Vanguard Group Inc. (9.80%), FMR LLC (9.63%), Wellington Management Group LLP (7.49%) and Driehaus Capital Management LLC (6.62%). Insiders that own company stock include Perceptive Advisors Llc, Richard Scott Struthers, Marc Wilson, Stephen F Betz, Jeff E Knight, Alan Seth Krasner, Dana Pizzuti, James Hassard, Matthew K Fust, Stephanie Okey and Coelho Rogerio Vivaldi.
View institutional ownership trends.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRNX
• CUSIP: N/A
• CIK: 1658247
• Web: www.crinetics.com
• Phone: (858) 450-6464
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $72.64
• High Stock Price Target: $97.00
• Low Stock Price Target: $54.00
• Potential Upside/Downside: +97.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-214,530,000.00
• Net Margins: N/A
• Pretax Margin: -26,298.27%
• Return on Equity: -36.12%
• Return on Assets: -31.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.39
• Quick Ratio: 16.38

Sales & Book Value

• Annual Sales: $1.04 million
• Price / Sales: 3,290.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.07 per share
• Price / Book: 4.57

Miscellaneous

• Outstanding Shares: 92,738,000
• Free Float: 87,174,000
• Market Cap: $3.42 billion
• Optionable: Optionable
• Beta: 0.56